Magnus Rizell

Magnus Rizell

Auto-generated profile, based on publicly available information

Magnus Rizell

Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ASAndreas A Schnitzbauer
Andreas A Schnitzbauer
CZCarl Zuelke
Carl Zuelke
CGChristian Graeb
Christian Graeb
JRJustine Rochon
Justine Rochon
IAItxarone BILBAO AGUIRRE
Itxarone BILBAO AGUIRRE
EGEdward K Geissler
Edward K Geissler
Background: The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) recipients with a pre-transplant diagnosis of HCC. Methods/Design: The study is an open-labelled, randomised, RCT comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing LT for HCC. Patients with a histologically confirmed HCC diagnosis are randomised into 2 groups within 4-6 weeks after LT; one arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol and the second arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol for the first 4-6 weeks, at which time sirolimus is initiated. A 21/2 -year recruitment phase is planned with a 5-year follow-up, testing HCC-free survival as the primary endpoint. Our hypothesis is that sirolimus use in the second arm of the study will improve HCC-free survival. The study is a non-commercial investigator-initiated trial (IIT) sponsored by the University Hospital Regensburg and is endorsed by the European Liver and Intestine Transplant Association; 13 countries within Europe, Canada and Australia are participating. Discussion: If our hypothesis is correct that mTOR inhibition can reduce HCC tumour growth while simultaneously providing immunosuppression to protect the liver allograft from rejection, patients should experience less post-transplant problems with HCC recurrence, and therefore could expect a longer and better quality of life. A positive outcome will likely change the standard of posttransplant immunosuppressive care for LT patients with HCC. Trial Register: Trial registered at http://www.clinicaltrials.gov: NCT00355862 (EudraCT Number: 2005-005362-36)

27 December 2006 in Transplantation
Verified
Journal Article
Closed access
IFIngela Fehrman-Ekholm
Ingela Fehrman-Ekholm
GNGunnela Nordén
Gunnela Nordén
ALAnnette Lennerling
Annette Lennerling
MRMagnus Rizell
Magnus Rizell
LMLars Mjörnstedt
Lars Mjörnstedt
MOMichael Olausson
Michael Olausson
Background. The increasing use of living kidney donors requires knowledge about long-term effects, especially number and causes of donors with end-stage renal disease (ESRD). Methods. A retrospective data analysis of 1,112 consecutive living kidney donors who underwent nephrectomy from 1965 until 2005 at Sahlgrenska University Hospital. Case reports were sought with help from nephrologists in the region and data from Swedish Registry of Active Uremic Treatment (SRAU). Results. The number of cases with end stage kidney failure among living kidney donors was 6/1112, that is 0.5%. The donors had reached ESRD during the years 2001–2006, that means 36–41 years after start of the living donor program. The donors were 45–89 years old, median 77 years, and five of six were males. Time since donation was 14–27 years, median 20 years, for the donors developing ESRD. The diagnoses were nephrosclerosis (4 cases), postrenal failure (1 case), and renal carcinoma (1 case). The expected incidence for development of ESRD according to incidence in the general population would have been two donors but we found six. However, considering the high age of the donors in this follow up, the age-matched incidence is calculated to be closer to six donors due to higher incidence in the aged. Conclusion. In all 0.5% of the donors developed ESRD. Due to high age of the uremic donors, there seems to be no increased incidence.

29 February 2008 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MRMagnus Rizell
Magnus Rizell
MAMats Andersson
Mats Andersson
CCChristian Cahlin
Christian Cahlin
LHLarsolof Hafström
Larsolof Hafström
MOMichael Olausson
Michael Olausson
PLPer Lindnér
Per Lindnér

1 September 2014 in Metabolism
Verified
Journal Article
Closed access
MPMaria Pereira
Maria Pereira
JPJenny Palming
Jenny Palming
MSMaria K. Svensson
Maria K. Svensson
MRMagnus Rizell
Magnus Rizell
JDJan Dalenbäck
Jan Dalenbäck
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson

1 May 2012 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
MPMaria Pereira
Maria Pereira
JPJenny Palming
Jenny Palming
MRMagnus Rizell
Magnus Rizell
Manuel AurelianoManuel Aureliano
Manuel Aureliano
ECEugenia Carvalho
Eugenia Carvalho
JEJan W. Eriksson
Jan W. Eriksson

1 June 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
Roger Olofsson BaggeRoger Olofsson Bagge
Roger Olofsson Bagge
ANAxel Nelson
Axel Nelson
ASAmir Shafazand
Amir Shafazand
CACharlotta All-Eriksson
Charlotta All-Eriksson
CCChristian Cahlin
Christian Cahlin
PLPer Lindnér
Per Lindnér
PURPOSE: About half of patients with metastatic uveal melanoma present with isolated liver metastasis, in whom the median survival is 6-12 months. The few systemic treatment options available only moderately prolong survival. Isolated hepatic perfusion (IHP) with melphalan is a regional treatment option, but prospective efficacy and safety data are lacking. METHODS: In this multicenter, randomized, open-label, phase III trial, patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with IHP with melphalan or best alternative care (control group). The primary end point was overall survival at 24 months. Here, we report the secondary outcomes of response according to RECIST 1.1 criteria, progression-free survival (PFS), hepatic PFS (hPFS), and safety. RESULTS: Ninety-three patients were randomly assigned, and 87 patients were assigned to either IHP (n = 43) or a control group receiving the investigator's choice of treatment (n = 44). In the control group, 49% received chemotherapy, 39% immune checkpoint inhibitors, and 9% locoregional treatment other than IHP. In an intention-to-treat analysis, the overall response rates (ORRs) were 40% versus 4.5% in the IHP and control groups, respectively ( P < .0001). The median PFS was 7.4 months versus 3.3 months ( P < .0001), with a hazard ratio of 0.21 (95% CI, 0.12 to 0.36), and the median hPFS was 9.1 months versus 3.3 months ( P < .0001), both favoring the IHP arm. There were 11 treatment-related serious adverse events in the IHP group compared with seven in the control group. There was one treatment-related death in the IHP group. CONCLUSION: IHP treatment resulted in superior ORR, hPFS, and PFS compared with best alternative care in previously untreated patients with isolated liver metastases from primary uveal melanoma.